l-asparaginase + azaribine + prednisone + azathioprine + 6-thioguanine

**l-Asparaginase + azaribine + prednisone + azathioprine + 6-thioguanine** is a multi-agent chemotherapy combination historically investigated for antineoplastic activity, primarily in hematologic malignancies such as acute lymphoblastic leukemia (ALL). **L-asparaginase** is an enzyme that depletes extracellular L-asparagine, leading to selective killing of asparagine-dependent leukemic cells lacking asparagine synthetase. **Azaribine** (prodrug of 6-azauridine) inhibits purine synthesis via orotidine monophosphate decarboxylase blockade. **Prednisone**, a synthetic glucocorticoid, induces lymphocytolysis and modulates immune responses through glucocorticoid receptor agonism. **Azathioprine**, a purine analog prodrug, is metabolized to 6-thioguanine nucleotides (6-TGN) that incorporate into DNA/RNA and inhibit purine biosynthesis. **6-Thioguanine** directly yields 6-TGN for cytotoxic DNA mismatch repair inhibition and apoptosis induction. This regimen leverages synergistic antimetabolite, enzyme depletion, and steroid mechanisms for combination chemotherapy, though specific clinical trial data for this exact pentad is limited; individual agents are standard in leukemia/lymphoma protocols with risks including pancreatitis (L-asparaginase, azathioprine, prednisone) and myelosuppression.